TargetBeta
BRD2
bromodomain containing 2 · also KIAA9001, RING3, D6S113E, NAT · Bromodomain and extra-terminal domain family
1 program in company-led studies act on BRD2, from 1 company: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| pelabresibrule | Novartis | phase 3 | 117 running | BRD3, BRD4, BRDT | ChEMBL |
Conditions their studies are in
- Hematologic Neoplasms, 1 program
- Lymphoma, 1 program
- Lymphoma, Follicular, 1 program
- Multiple Myeloma, 1 program
- Primary Myelofibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 9, 2028pelabresib · Novartis · phase 3 · NCT07340190
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.